Rev-Med
Rev-Med focuses on technical innovation in regenerative medicine solutions and bioengineering technologies.
- Company typePrivate
- Founded2009
- HeadquartersSeongnam, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Rev-Med does
Rev-Med focuses on technical innovation in regenerative medicine solutions and bioengineering technologies.
Rev-Med firmographics
Firmographics- Name
- Rev-Med
- Legal name
- REV-MED
- Website
- https://rev-med.co.kr/
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Rev-Med focuses on technical innovation in regenerative medicine solutions and bioengineering technologies.
- Ownership category
- akta.pro rank
Rev-Med industry classification
Industry- Product category
- Regenerative Medicine Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Point-of-Care Regenerative Kits & Devices (Processing/Delivery) (HLAMANAK)
- akta.pro secondary industries
- Stem Cell–Based Regenerative Therapies (HLAAAGAA), Platelet-Rich Plasma (PRP) & Blood-Derived Orthobiologics (HLAMANAB), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
Keywords
Where Rev-Med is headquartered
LocationHeadquarters
- HQ city
- Seongnam
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
Rev-Med business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Biologics Processing Kits: Sale of proprietary cell processing and concentration kits including NovaStem BC, NovaStem BMAC, TriCell PRP, and DuoCell SVF for clinical applications in regenerative medicine, orthopedics, and aesthetic procedures.
- Medical Devices: Sale of aesthetic and medical equipment including ReWave (ultra-high-frequency microwave device), Hilthera 4.0 (high-power laser platform), and Brifill (HA filler products).
- Consulting Services: Advanced Regenerative Medicine Institution consulting services for designation and clinical research operations, leveraging proprietary technologies and regulatory expertise.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Rev-Med product offering
Product offeringCore offering
REV-MED develops, manufactures, and sells proprietary biologics processing kits and medical devices for the separation and concentration of autologous cells from blood, bone marrow, and adipose tissue. Its core offering centers on a patented triple-chamber separation system used across the TriCell PRP, NovaStem BC/BMAC, and DuoCell SVF product lines, complemented by aesthetic medical devices (Hilthera 4.0, ReWave, OnyRay) and HA fillers (Brifill). These products enable hospitals, clinics, and aesthetic practices to deliver standardized regenerative, orthopedic, anti-aging, and de-aging procedures.
Product overview
REV-MED offers an integrated portfolio of regenerative medicine products centered on autologous cell separation and concentration technologies. The core portfolio includes TriCell PRP and NovaStem (BC/BMAC) kits for extracting and concentrating platelets, stem cells, and immune cells from blood and bone marrow, alongside DuoCell SVF for adipose-derived cells. The company also provides aesthetic medical devices including Hilthera 4.0 (high-power laser), ReWave (ultra-high-frequency microwave device), and OnyRay (dental/medical device), as well as Brifill HA fillers. These products are unified by REV-MED's proprietary 3-chamber technology and closed-system designs that enable minimally manipulated biological extraction for applications spanning orthopedic, aesthetic, anti-aging, and de-aging medicine.
Differentiator
Problem solved
Functional benefit
Brands
- NovaStem: Autologous cell concentration platform for separating and concentrating cells from blood and bone marrow
- TriCell
- ReWave
- Hilthera 4.0
- Brifill
- DuoCell SVF
Products and services
- TriCell PRP Platelet-rich plasma (PRP) extraction kit utilizing double-spin centrifugation combined with a 3-chamber system to separate and concentrate highly concentrated platelets and growth factors from autologous blood for tissue regeneration and pain management applications.
- PRP UNI PRP extraction product designed for separating and concentrating platelets from autologous blood for clinical applications.
- NovaStem BC Autologous blood-derived cell concentration platform that separates and concentrates hematopoietic stem cells, T cells, NK cells, and other cellular components from a patient's own blood through a patented 3-chamber system and closed-system design for anti-aging, de-aging, and musculoskeletal applications.
- NovaStem BMAC Autologous bone marrow-derived cell concentration platform that separates and concentrates bone marrow aspirate concentrate (BMAC) through a patented 3-chamber system and fully closed processing structure for musculoskeletal and regenerative medicine applications.
- DuoCell SVF Adipose-derived stromal vascular fraction (SVF) processing kit that separates and concentrates cells from adipose tissue through a minimally manipulated processing method.
- Hilthera 4.0 High-power laser platform for non-surgical regenerative and aesthetic solutions.
- OnyRay Dental/medical device for imaging or treatment applications.
- OnyRay S Variant model of the OnyRay medical device product line.
- ReWave Ultra-high-frequency microwave-based aesthetic device for skin regeneration, collagen boosting, and lifting treatments.
- Brifill Hyaluronic acid (HA) filler product for aesthetic medicine applications.
- Advanced Regenerative Medicine Institution Consulting Service Consulting service that supports hospitals and clinics in obtaining Advanced Regenerative Medicine Institution designation and clinical research operations, leveraging REV-MED's proprietary autologous biologics technologies and regulatory expertise.
Quantifiable outcome
- Blood serotonin levels increased approximately 21% following intravenous administration of NovaStem BC concentrate compared with pre-treatment levels (P < 0.0381, n=6)
- +2 more outcomes
Companies that use Rev-Med
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Rev-Med technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Rev-Med partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- BioPlus InternationalcoreStrategic partnership to advance next-generation bio-beauty solutions. Collaboration aims to combine REV-MED's autologous biologics technology with BioPlus International's capabilities to develop innovative products in the beauty and wellness sector.
- MedicompactminorStrategic partnership to promote health and aesthetic information services. Collaboration focuses on marketing and awareness building for regenerative medicine and aesthetic solutions.
- Korea Racing AuthorityminorJoint research collaboration to develop customized treatment protocols for racehorses using REV-MED's autologous cell technologies, expanding applications into veterinary regenerative medicine.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Rev-Med competitors and assessment
Company assessmentDirect peers
- Arthrex: Global orthopedic medical device leader with a dedicated autologous PRP and orthobiologics product line (Angel System, ACP). Directly comparable as it sells point-of-care PRP kits and biologic-processing devices to the same orthopedic and sports medicine customer base.
- EmCyte Corporation: US-based manufacturer of PRP and autologous biologics concentration kits (e.g., PurePRP, Genesis). Closely comparable to REV-MED's TriCell PRP offering in product architecture, customer profile (orthopedic and aesthetic clinics), and point-of-care minimally manipulated processing approach.
- Isto Biologics: Orthobiologics company offering bone marrow aspirate and autologous cell therapies for spine and orthopedic applications. Comparable to REV-MED's NovaStem BMAC line in musculoskeletal regenerative medicine positioning and clinical use cases.
- GID Group: Cell-processing company specializing in adipose-derived SVF preparation kits for regenerative aesthetics and orthopedics. Directly comparable to REV-MED's DuoCell SVF platform in technology and target clinical use cases.
- Royal Biologics: Orthobiologics and autologous cell therapy company providing amniotic, placental, and PRP-based products. Comparable as a focused orthobiologics competitor selling regenerative kits to orthopedic and sports medicine physicians.
- Bimini Health Tech (formerly Cytori Therapeutics): Regenerative medicine company with adipose-derived SVF cell processing platforms for aesthetics and orthopedics. Directly comparable to REV-MED's DuoCell SVF in cell source, target indications, and minimally manipulated processing approach.
Broad incumbents
- Zimmer Biomet (Regenexx): Global orthopedic device giant whose Regenexx network offers autologous stem-cell and PRP treatments. Comparable as a broad incumbent offering autologous biologics alongside a much wider orthopedic device portfolio.
- Terumo BCT: Division of Terumo specializing in blood component and cell processing systems used in hospitals and cell-therapy labs. Comparable as a broad incumbent in cell/biologic separation technology, though its scale and hospital focus differ from REV-MED's point-of-care clinic model.
- Miltenyi Biotec: Major cell biology and cell therapy tools provider, including autologous cell separation instruments. Comparable as a broad incumbent whose cell-processing equipment overlaps with REV-MED's separation/concentration technology, though Miltenyi operates at greater scale and in lab-based rather than point-of-care settings.
Emerging players
- BioRestorative Therapies: Small US-listed cell therapy company developing autologous stem-cell therapies for disc/spine and metabolic indications. Comparable as an emerging regenerative medicine peer addressing musculoskeletal indications with autologous cell platforms, though with a more therapy-as-drug rather than kit-based business model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Rev-Med social profiles
Digital presenceRev-Med compliance and trust
Trust signalCompliance2 records
Rev-Med financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rev-Med leadership team
Management profileNumber of profiles
Profiles2 records
Rev-Med funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rev-Med M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rev-Med
What does Rev-Med do?
REV-MED develops, manufactures, and sells proprietary biologics processing kits and medical devices for the separation and concentration of autologous cells from blood, bone marrow, and adipose tissue. Its core offering centers on a patented triple-chamber separation system used across the TriCell PRP, NovaStem BC/BMAC, and DuoCell SVF product lines, complemented by aesthetic medical devices (Hilthera 4.0, ReWave, OnyRay) and HA fillers (Brifill). These products enable hospitals, clinics, and aesthetic practices to deliver standardized regenerative, orthopedic, anti-aging, and de-aging procedures.
Is Rev-Med a public or private company?
Rev-Med is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Rev-Med founded?
Rev-Med was founded in 2009. It employs 11 to 50 people.
Where is Rev-Med based?
Rev-Med is headquartered in Seongnam, South Korea, in the Asia region.
How does Rev-Med make money?
Three revenue lines are on record. Biologics Processing Kits are the primary driver. The others are medical Devices and consulting Services.
Who are Rev-Med's main competitors?
Direct peers on record are Arthrex, EmCyte Corporation, Isto Biologics, GID Group, Royal Biologics and Bimini Health Tech (formerly Cytori Therapeutics). Broad incumbents are Zimmer Biomet (Regenexx), Terumo BCT and Miltenyi Biotec. BioRestorative Therapies is listed as an emerging player.
Does Rev-Med have an API?
No public API is recorded for Rev-Med.
What industry is Rev-Med in?
Rev-Med's product category is Regenerative Medicine Medical Devices. Its primary akta.pro industry code is HLAMANAK, Point-of-Care Regenerative Kits & Devices (Processing/Delivery), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 339112 and its SIC code is 3841.